INTRODUCTION {#s1}
============

According to GlOBACAN 2012, gastric cancer (GC) is the fifth most common cancer in terms of incidence and the third-leading cause of cancer death worldwide. Moreover, half of the world\'s GC occurs in Eastern Asia, primarily China \[[@R1]\]. Currently, the reliable methods for identifying subjects who are at a high risk of GC are still limited to gastroscopy and biopsy, but these methods are invasive, expensive and time-consuming \[[@R2], [@R3]\]. Therefore, noninvasive and acceptable biomarkers for GC are urgently needed.

*Helicobacter pylori (H. pylori)* has been classified as a type-1 carcinogen by the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) \[[@R4]\]. A meta-analysis of 42 studies demonstrated that *H. pylori* infection is associated with a 2-fold increase in the risk of developing gastric adenocarcinoma \[[@R5]\]. Additionally, another meta-analysis revealed a reduction in the risk of GC following *H. pylori* eradication with a pooled RR of 0.65 \[[@R6]\]. Thus, population-wide screening for and eradication of *H. pylori* infection may be a valid strategy for GC prevention. However, although more than half of the world\'s population is infected with *H. pylori* \[[@R7]\], the majority of individuals infected with this bacterium are completely asymptomatic and do not demonstrate any severe pathology throughout their lives. Only 1-3% of infected individuals will eventually develop GC \[[@R8], [@R9]\]. Therefore, it has been postulated that these different outcomes of infection may be partly due to differences in the virulence factors of the infecting *H. pylori* strains \[[@R10]\].

*H. pylori* has a wide variety of immunogenic virulence factors, and the host responses directed against these factors accordingly generate different immune patterns that may be associated with the pathogen-related GC risk to some extent \[[@R11]\]. One study reported that seropositivities for four proteins (i.e., Omp, HP0305, HyuA, and HpaA) are associated with 1.5- to three-fold increases in the risk of GC among Chinese populations \[[@R12]\]. GroES is a dominant GC-related antigen with a much higher seropositivity in GC cases (64.2%) compared with gastritis (30.9%) and duodenal ulcer cases (35.5%) \[[@R13]\]. However, these studies only examined the associations of *H. pylori* virulence factors with GC risk and did not assess the validities of these factors as GC screening markers.

The flagellar hook-associated protein (FliD) is an important *H. pylori* virulence factor that enables flagellin monomers to assemble into a flagella and is thus essential to bacterial motility as demonstrated by infections of mice with a *fliD*-mutant *H. pylori* \[[@R14]\]. Flagella-providing motility further contributes to *H. pylori* colonization and infection \[[@R15]--[@R17]\]. Additionally, the FliD protein induces specific antibodies in nearly all infected individuals \[[@R18]\]. Therefore, we performed the present study to assess the association between seropositivity for the antibody against *H. pylori* FliD and the risk of GC and to explore the application of the serum FliD antibody as a novel biomarker for GC. Furthermore, we also studied and assessed the screening value of the antibody against the typical virulence factor cytotoxin-associated gene A (CagA). We further explored the combined screening validity of FliD, CagA, flagellin A (FlaA), and neutrophil-activating protein (NapA), which are proteins that we have previously studied \[[@R19], [@R20]\].

RESULTS {#s2}
=======

Subject characteristics {#s2_1}
-----------------------

The basic demographic and clinical characteristics, behavior, family history of GC and serologic test results for *H. pylori* are presented in Table [1](#T1){ref-type="table"}. The differences in the BMI, years of education, smoking, alcohol consumption, *H. pylori* infection and family history of GC distributions between the cases and controls were statistically significance (*\*p*\<0.05). Of the 232 patients with GC, only 9 had gastric cardia cancer; 14 (7.2%) of the cases were in stage I, 16 (8.2%) were in stage II, 143 (73.7%) were in stage III, and 21 (10.8%) were in stage IV. The rates of seropositivity for *H. pylori* in the case and control groups were 59.7% and 48.0%, respectively.

###### Characteristics of the study subjects

  Variables                          Case (N=232)   Control (N=266)   *P*[^\*^](#tfn_001){ref-type="table-fn"}          
  ---------------------------------- -------------- ----------------- ------------------------------------------ ------ ---------
  Age (years, mean ± SD)             59.6 ± 10.6    57.7 ± 10.6       0.055                                             
  Sex                                                                                                                   
   Male                              174            75.0              179                                        67.3   0.059
   Female                            58             25.0              87                                         32.7   
  BMI                                                                                                                   
   \<18.5                            24             11.8              2                                          0.8    \<0.001
   18.5-24.9                         135            66.5              174                                        67.2   
   25.0-29.9                         36             17.7              76                                         29.3   
   ≥30.0                             8              3.9               7                                          2.7    
  Years of education                                                                                                    
   ≤ 8                               131            63.9              151                                        57.9   0.019
   9-11                              46             22.4              87                                         33.3   
   ≥ 12                              28             13.7              23                                         8.8    
  Smoking status                                                                                                        
   Ever                              133            65.5              119                                        45.6   \<0.001
   Never                             70             34.5              142                                        54.4   
  Alcohol drinking status                                                                                               
   Ever                              121            59.3              99                                         38.1   \<0.001
   Never                             83             40.7              161                                        61.9   
  *H. pylori* serostatus                                                                                                
   Positive                          132            59.7              120                                        48.0   0.011
   Negative                          89             40.3              130                                        52.0   
  Family history of gastric cancer                                                                                      
   Positive                          20             10.1              2                                          0.8    \<0.001
   Negative                          179            89.9              259                                        99.2   
  Locations                                                                                                             
   Non cardia                        223            96.1                                                                
   Cardia                            9              3.9                                                                 
  Depth of invasion                                                                                                     
   T1                                17             9.2                                                                 
   T2                                12             6.5                                                                 
   T3                                15             8.2                                                                 
   T4                                140            76.1                                                                
  Lymph node metastasis                                                                                                 
   N0                                68             37.8                                                                
   N1                                28             15.6                                                                
   N2                                29             16.1                                                                
   N3                                55             30.6                                                                
  Distant metastasis                                                                                                    
   M0                                179            89.5                                                                
   M1                                21             10.5                                                                
  Clinical stage                                                                                                        
   I                                 14             7.2                                                                 
   II                                16             8.2                                                                 
   III                               143            73.7                                                                
   IV                                21             10.8                                                                

*P* values were obtained from t-tests and chi-square tests.

Cloning and expression of the recombinant protein {#s2_2}
-------------------------------------------------

The nucleotide homology of the 2058-bp cloned *fliD* gene relative to *H. pylori* strain J99 was 94.41% ([Supplementary Figure S1](#SD2){ref-type="supplementary-material"}) \[[@R21]\]. The amplified *cagA* fragment was exactly 2247 bp, and the homology with *H. pylori* strain 26695 was 99.96% ([Supplementary Figure S2](#SD3){ref-type="supplementary-material"}) \[[@R22]\]. After adding IPTG, bands of rFliD and rCagA with predicted molecular weights of 92 kDa and 103 kDa were found, respectively, in the ultrasonic supernatants and precipitates of the cell lysates by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Finally, the purified soluble recombinant proteins were obtained (Figure [1](#F1){ref-type="fig"}).

![SDS-PAGE analyses of the purified recombinant proteins\
**A.** FliD. **B.** CagA.](oncotarget-07-22397-g001){#F1}

Association between seropositivity for FliD and CagA antibody and GC {#s2_3}
--------------------------------------------------------------------

As illustrated in Table [2](#T2){ref-type="table"}, the associations between *H. pylori* FliD serum antibody and GC were statistically significant with adjusted odds ratios (ORs) (95%CIs) of 10.6 (5.2-21.6), 6.5 (3.0-14.0), and 7.6 (4.7-12.3) in the *H. pylori*-positive and -negative subjects and the overall subjects (i.e., irrespective of *H. pylori* status), respectively (*\*p*\<0.001). Strong, significant dose-response relationships between the serum FliD antibody levels and GC were observed in these three populations (*\*p*\<0.001; Table [3](#T3){ref-type="table"}).

###### Associations of seropositivities for FliD and CagA antibodies with GC in the study subjects

  Virulence factor serostatus   *H. pylori*-positive subjects   *H. pylori*-negative subjects   Overall subjects                                                                                                             
  ----------------------------- ------------------------------- ------------------------------- ------------------ --------- ----------- ----------- ----------------- --------- ------------ ------------ ----------------- ---------
  FliD                                                                                                                                                                                                                       
   Negative                     43 (32.6)                       99 (82.5)                       1.0 (Reference)    \<0.001   15 (16.9)   58 (44.6)   1.0 (Reference)   \<0.001   49 (21.1)    171 (64.3)   1.0 (Reference)   \<0.001
   Positive                     89 (67.4)                       21 (17.5)                       10.6 (5.2-21.6)              74 (83.1)   72 (55.4)   6.5 (3.0-14.0)              183 (78.9)   95 (35.7)    7.6 (4.7-12.3)    
  CagA                                                                                                                                                                                                                       
   Negative                     24 (18.2)                       51 (42.5)                       1.0 (Reference)    0.001     24 (27.0)   56 (43.1)   1.0 (Reference)   \<0.001   78 (33.6)    150 (56.4)   1.0 (Reference)   \<0.001
   Positive                     108 (81.8)                      69 (57.5)                       3.0 (1.6-5.9)                65 (73.0)   74 (56.9)   3.8 (1.9-7.7)               154 (66.4)   116 (43.6)   2.5 (1.6-3.8)     

Adjusted for age, sex, BMI, education, smoking, alcohol consumption and family history of gastric cancer.

###### Dose-dependent associations of GC risk with serum FliD and CagA antibody levels in the study subjects

  *H*. pylori positive subjects   *H. pylori* negative subjects   overall subjects                                                                                                                                                                
  ------------------------------- ------------------------------- ------------------ ------------------- --------- --------------- ----------- ----------- ----------------- --------- --------------- ------------ ----------- ----------------- ---------
  FliD                                                                                                                                                                                                                                            
   \> 0.1914                      2 (1.5)                         30 (25.0)          1.0 (Reference)     \<0.001   \> 0.1906       2 (2.3)     32 (24.6)   1.0 (Reference)   \<0.001   \> 0.1841       6 (2.6)      66 (24.8)   1.0 (Reference)   \<0.001
   0.1313-0.1914                  12 (9.1)                        30 (25.0)          6.0 (1.4-25.2)                0.1345-0.1906   10 (11.2)   33 (25.4)   4.8 (1.2-19.7)              0.1345-0.1841   19 (8.2)     67 (25.2)   3.1 (1.3-7.7)     
   0.1057-0.1313                  22 (16.7)                       29 (24.2)          11.4 (2.6-49.1)               0.0932-0.1345   26 (29.2)   33 (25.4)   12.6 (3.5-44.7)             0.1028-0.1345   49 (21.1)    67 (25.2)   8.0 (3.5-18.4)    
   ≤ 0.1057                       96 (72.7)                       31 (25.8)          46.5 (14.7-147.1)             ≤ 0.0932        51 (57.3)   32 (24.6)   25.5 (7.0-93.1)             ≤ 0.1028        158 (68.1)   66 (24.8)   26.3(13.7-50.6)   
  CagA                                                                                                                                                                                                                                            
   \> 0.0544                      17 (12.9)                       30 (25.0)          1.0 (Reference)     \<0.001   \> 0.0530       10 (11.2)   31 (23.8)   1.0 (Reference)   \<0.001   \> 0.0531       29 (12.5)    66 (24.8)   1.0 (Reference)   \<0.001
   0.0400-0.0544                  23 (17.4)                       29 (24.2)          1.4 (0.6-3.0)                 0.0387-0.0530   10 (11.2)   33 (25.4)   0.9 (0.2-5.0)               0.0393-0.0531   37 (15.9)    63 (23.7)   1.3 (0.8-2.3)     
   0.0291-0.0400                  33 (25.0)                       31 (25.8)          1.9 (0.9-4.1)                 0.0270-0.0387   23 (25.9)   33 (25.4)   2.2 (0.9-5.7)               0.0280-0.0393   61 (26.3)    68 (25.6)   2.0 (1.1-3.5)     
   ≤ 0.0291                       59 (44.7)                       30 (25.0)          3.5 (1.7-7.4)                 ≤ 0.0270        46 (51.7)   33 (25.4)   4.3 (1.8-10.3)              ≤ 0.0280        105 (45.3)   69 (25.9)   3.5 (2.1-5.8)     

The Seropositivities for the antibody to FliD were categorized by antibody level quartiles in the controls.

As presented in Table [2](#T2){ref-type="table"}, seropositivity for the CagA antibody was also significantly linked to the risk of GC with OR~adjusted~ (95% CI) values of 3.0 (1.6-5.9), 3.8 (1.9--7.7), and 2.5 (1.6--3.8) in the *H. pylori*-positive and -negative subjects and the overall subjects, respectively (*\*p*\<0.01). Significant dose-response relationships between the serum CagA antibody levels and GC were also observed (*\*p*\<0.001; Table [3](#T3){ref-type="table"}).

Screening utilities of the serum FliD and CagA antibodies for GC {#s2_4}
----------------------------------------------------------------

According an receiver operating characteristic (ROC) analysis of FliD in the *H. pylori*-positive subjects, the optimal FliD cutoff value for GC was 0.1007, which provided a sensitivity of 67.4% and a specificity of 82.5%. The optimal cutoff value was 0.1263 for the *H. pylori*-negative subjects, which resulted in a sensitivity of 83.1% and a specificity of 55.4%. The optimal FliD cutoff value was 0.1153 in the overall group of subjects, and this cutoff generated a sensitivity of 78.9% and a specificity of 64.3%. When the optimal CagA cutoff values were set at 0.0463, 0.0367 and 0.0463 for the *H. pylori*-positive, *H. pylori*-negative and overall subjects, the sensitivities were 81.8%, 73.0% and 83.2%, and the specificities were 42.5%, 56.9% and 39.1%, respectively (Table [4](#T4){ref-type="table"}). The areas under ROC curves (AUCs) for FliD and CagA were 0.800 and 0.653, respectively, in the overall groups of subjects (Figure [2](#F2){ref-type="fig"}).

###### Sensitivities and specificities at different FliD and CagA critical values

                                                              *H. pylori* positive subjects   *H. pylori* negative subjects   Overall subjects                                          
  ----------------------------------------------------------- ------------------------------- ------------------------------- ------------------ -------- ------ ------ -------- ------ ------
  FliD                                                                                                                                                                                  
   Optimal cutoff point[^b^](#tfn_006){ref-type="table-fn"}   0.1007                          67.4                            82.5               0.1263   83.1   55.4   0.1153   78.9   64.3
   25%                                                        0.1057                          72.0                            75.8               0.0932   57.3   75.4   0.1028   68.1   75.2
   50%                                                        0.1313                          89.4                            50.0               0.1345   86.5   50.0   0.1345   89.2   50.0
   75%                                                        0.1914                          98.5                            25.0               0.1906   97.8   24.6   0.1841   97.4   24.8
   90%                                                        0.2694                          100.0                           10.0               0.2688   98.9   10.0   0.2676   99.6   9.8
  CagA                                                                                                                                                                                  
   Optimal cutoff point[^b^](#tfn_006){ref-type="table-fn"}   0.0463                          81.8                            42.5               0.0367   73.0   56.9   0.0463   83.2   39.1
   25%                                                        0.0291                          44.7                            75.0               0.0270   50.6   76.9   0.0280   45.3   75.9
   50%                                                        0.0400                          68.9                            50.8               0.0387   77.5   50.8   0.0393   70.7   50.4
   75%                                                        0.0544                          87.1                            25.0               0.0530   88.8   25.4   0.0531   87.5   24.8
   90%                                                        0.0696                          97.0                            10.0               0.0716   96.6   10.0   0.0701   96.6   9.8

Percentiles of the serum FliD antibody levels in the controls;

*Sn*, Sensitivity; *Sp*, Specificity.

The optimal cutoff points for the different biomarkers were based on the maximum Youden\'s indices (sensitivity + specificity-1).

![Receiver operating characteristic (ROC) curves of the predictive performances of the serum FliD antibody, CagA antibody and the combination of FliD, FlaA and NapA antibodies in the overall subjects](oncotarget-07-22397-g002){#F2}

Screening utility of the combination of the serum FliD, CagA, FlaA and NapA antibodies for GC {#s2_5}
---------------------------------------------------------------------------------------------

In the present paper, the combined screening validities of FliD, FlaA, NapA and CagA generated by discriminant analysis were also analyzed. As illustrated in Table [5](#T5){ref-type="table"}, the AUC and sensitivity of the combination of FliD and FlaA was significantly greater than that of FliD alone. Regarding the combination of FliD, FlaA and NapA, although the AUC was not significantly increased compared to that of the combination of FliD and FlaA, the sensitivity (at the specificity of 90%) was significantly increased by 10.6% in the *H. pylori*-positive subjects. Similarly, in *H. pylori*-negative and overall subjects, the sensitivities (at specificities of 95%) were significantly increased by 15.7% and 9.1%, respectively, relative to the combination of FliD and FlaA. Moreover, the AUCs for the combination of FliD, FlaA, NapA and CagA were not significantly greater than those of the combination of FliD, FlaA and NapA among the three populations mentioned above.

###### AUCs and sensitivities of the combination of FliD, FlaA, NapA and CagA for GC

  Marker combination              AUC (95% CI)          *p*-value for comparison of AUC to FliD   90% Specificity (%)   95% Specificity (%)   98% Specificity (%)   *p*-value for comparison of sensitivity at 95% specificity to FliD
  ------------------------------- --------------------- ----------------------------------------- --------------------- --------------------- --------------------- --------------------------------------------------------------------
  *H. pylori*-positive subjects                                                                                                                                     
   FliD                           0.821 (0.768-0.867)   N/A                                       56.1                  39.4                  22.7                  N/A
   FliD+ FlaA                     0.913 (0.871-0.945)   \<0.001                                   66.7                  60.6                  50.0                  \<0.001
   FliD+ NapA                     0.822 (0.769-0.867)   0.657                                     56.1                  40.9                  25.0                  0.617
   FliD+ FlaA+NapA                0.918 (0.877-0.949)   \<0.001                                   77.3                  61.4                  53.0                  \<0.001
   FliD+ FlaA+NapA+CagA           0.916 (0.875-0.947)   \<0.001                                   72.0                  62.9                  51.5                  \<0.001
  *H. pylori*-negative subjects                                                                                                                                     
   FliD                           0.764 (0.702-0.818)   N/A                                       30.3                  25.8                  14.6                  N/A
   FliD+ FlaA                     0.891 (0.842-0.929)   \<0.001                                   61.8                  36.0                  24.7                  0.164
   FliD+ NapA                     0.791 (0.731-0.843)   0.094                                     42.7                  22.5                  14.6                  0.579
   FliD+ FlaA+NapA                0.897 (0.849-0.934)   \<0.001                                   60.7                  51.7                  29.2                  \<0.001
   FliD+ FlaA+NapA+CagA           0.908 (0.862-0.943)   \<0.001                                   65.2                  47.2                  22.5                  0.004
  Overall subjects                                                                                                                                                  
   FliD                           0.800 (0.762-0.834)   N/A                                       32.8                  21.1                  12.5                  N/A
   FliD+ FlaA                     0.907 (0.878-0.931)   \<0.001                                   54.3                  43.1                  31.9                  \<0.001
   FliD+ NapA                     0.805 (0.767-0.839)   0.278                                     33.6                  22.4                  14.7                  0.450
   FliD+ FlaA+NapA                0.915 (0.887-0.938)   \<0.001                                   61.6                  52.2                  33.2                  \<0.001
   FliD+ FlaA+NapA+CagA           0.915 (0.887-0.938)   \<0.001                                   63.8                  44.0                  27.2                  \<0.001

DISCUSSION {#s3}
==========

Currently, most countries lack national strategies or recommendations for early GC detection because no good screening methods are available. Hence, screening tests that can reliably evaluate GC subjects are urgently needed.

It has been proposed that the colonization of the gastric mucosa is a prerequisite for *H. pylori* infection and carcinogenesis and that motility is also essential for the initial colonization \[[@R17], [@R23], [@R24]\]. Flagella have been generally regarded as important virulence factors of pathogenic bacteria primarily because of the associated motility properties \[[@R25]\]. The FliD protein is thought to function as a capping structure at the distal end of the filament to assemble into a flagella \[[@R26], [@R27]\]. To our knowledge, only a single study, Kimmel et al. has examined the association between the FliD antibody and GC, and no association was found \[[@R28]\]. In the present study, seropositivity for the FliD antibody was associated with a 10.6-fold increase in the risk of GC. Our result is not in line with that of Kimmel et al., which may be attributable to the small sample size in the latter study (4 cases and 5 controls) or the existing diversity of *H. pylori* and genetic differences in host immune responses to *H. pylori* infection.

In the present study, a commercial ELISA method was used to detect the *H. pylori* infection statuses of the subjects. However, some studies have indicated that commercial ELISA serology may fail to detect past *H. pylori* infections and that patients with negative *H. pylori* serologic tests can actually be positive for anti-CagA antibodies \[[@R29], [@R30]\]. At this point, the associations between GC and seropositivity for the FliD antibody were also analyzed in the *H. pylori*-negative and overall subjects. Additionally, strong, significant dose-response relationships between serum FliD antibody levels and GC were observed. These data suggest that attention should be focused on the antibody titer in addition to seropositivity.

Although CagA is an important and best-studied virulence factor of *H. pylori*, the association between the CagA antibody and the risk of GC remains controversial \[[@R31]\]. In the present study, we cloned a relatively conserved 2247-bp fragment of *cagA* extending from the 67^th^ to the 2313^th^ bp to express the CagA protein because the fragments of approximately 65 bp starting from the 5′-end of the *cagA* genes of different *H. pylori* isolates exhibit frequent mutations, and a variable EPIYA region at the C-terminus and an important cleavage site preceding the first EPIYA motif also exist \[[@R32]--[@R34]\]. The OR for the risk of GC based on the anti-CagA antibody was higher in the *H. pylori*-negative population than in the *H. pylori*-positive and total populations. Our result is consistent with the result of a meta-analysis that suggested that *H. pylori*-negative/CagA-positive subjects may represent the group with the highest risk for GC \[[@R31]\]. However, the AUC for the CagA antibody in all subjects was 0.653. AUCs in the range of 0.97 and above are generally considered to have excellent accuracies, AUCs of 0.93 to 0.96 are considered very good, AUCs of 0.75 to 0.92 are considered good, and AUCs below 0.75 should be cautiously evaluated because the associated tests have obvious deficiencies in accuracy that are approaching random \[[@R35], [@R36]\]. According to these standard, the accuracy of CagA in the screening of the GC population in our study was poor, and this result is consistent with the conclusion of a meta-analysis that indicated that the CagA antibody should not be used as a GC marker in East Asian countries due to its AUC of 0.636 \[[@R37]\]. Therefore, we focused on other potentially carcinogenic *H. pylori* virulence factors including FliD.

Although gastroscopy and biopsy are reliable methods for GC detection, these procedures are invasive, time-consuming and expensive; therefore, it is necessary to search for ideal biomarkers of GC. Many conventional biomarkers, such as the carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and cancer antigen 72-4 (CA72-4), are widely utilized in the clinic, but low sensitivities or low specificities reduce the clinical practical value of these markers for the early diagnosis of GC \[[@R38]--[@R40]\]. With the increase quantity of in-depth research into biomarkers for GC, increasing attention has been focused on the use of circulating nucleic acids as novel biomarkers. However, DNA/RNA extraction and bisulfite conversion are too time-intensive for clinical use \[[@R41]--[@R43]\]. Therefore, additional studies should be performed to identify the most promising markers for the potential future screening of GC. Emerging evidence has revealed that many *H. pylori* virulence factors promote the development of GC \[[@R44]\]. Additionally, seropositivities for antibodies against some of these *H. pylori* virulence factors have been identified as biomarkers of GC \[[@R45], [@R46]\]. The *H. pylori* flagellar virulence factor FliD has been identified as an efficient tool for the detection of *H. pylori* infections via measurements of the levels of the antibody to this factor in the serum \[[@R18]\]. In the present study, we explored the value of the serum FliD antibody as a biomarker for distinguishing GC patients from controls. Additionally, the significance of combinations of the FliD, FlaA, NapA and CagA antibodies were assessed. We found that FliD may be an independent biomarker based on the associated AUC of 0.800 in the overall group subjects and that the combination of FliD, FlaA and NapA exhibited a higher validity in the detection of GC with the AUC of 0.915.

Overall, the FliD antibody may be an independent biomarker for GC patients, and the combination of FliD, FlaA and NapA performed even better. However, our findings were obtained in a case-control study, and additional larger prospective studies are needed to expand and confirm these findings.

MATERIALS AND METHODS {#s4}
=====================

Study subjects {#s4_1}
--------------

A hospital-based case-control study was performed in Harbin, Heilongjiang Province, China. All 232 cases with pathologically confirmed GC were enrolled from the Third Affiliated Hospital of Harbin Medical University between March and June of 2010. Additionally, 183 healthy individuals who underwent physical examinations at the Center for Disease Control of Xiangfang District, Harbin between April and July of 2010 and 83 cancer-free neurological patients of the Fourth Affiliated Hospital of Harbin Medical University between March and May of 2011 were included as controls. All participants completed a face-to-face questionnaire and provided written informed consent. A blood sample was drawn from each consenting participant according to a research protocol approved by the Human Research and Ethics Committee of Harbin Medical University. All blood samples were centrifuged and stored at −80°C until use.

Serologic tests for *H. pylori* by ELISA {#s4_2}
----------------------------------------

*H. pylori* IgG antibodies were measured in duplicate using an enzyme immunoassay kit (IBL, Germany). The sensitivity and specificity of the kit were both greater than 95% according to the manufacturer.

Recombinant protein cloning and expression {#s4_3}
------------------------------------------

The genomic DNA of a clinical strain provisionally named HLJ014a was extracted using a DNA extraction kit (Qiagen, USA) and stored at −80°C. Briefly, the full-length fliD gene was amplified by polymerase chain reaction (PCR) using the genomic DNA as the template. Oligonucleotide primers were designed based on the published literature \[[@R18]\]. Subsequently, EcoRI sites were introduced into the 5′ ends of the forward primers, and XhoI sites were inserted into the 5′ ends of the reverse primers. The target DNA amplification product was cloned into the *pMD19T (simple)* cloning vector and then transformed into *E. coli* strain DH5α. The positive recombinants were confirmed by bacterial solution PCR, restriction enzyme digestion and DNA sequencing. The digested gel-purified *fliD* gene was ligated into the expression vector *pET-32a(+)*. The recombinant plasmid *pET32a-fliD* was transformed into *E. coli* BL21DE3 cells, transformation was confirmed, and the cells were inoculated into LB medium with 100 μg/mL ampicillin. Expression was induced via the addition of IPTG at a final concentration of 1.0 mmol/L at 30°C and an optical density (OD) of 0.6-0.8. The *E. coli* cells were harvested after 4 hours and lysed via ultrasonication. The suspension was collected and examined with 15% SDS-PAGE. The soluble histidine-tagged protein was purified with Ni-NTA His Bind resin (Novagen, Germany).

We also used the method described above to obtain the purified CagA protein. For the PCR, the primers were designed to amplify a relatively conserved 2247-bp *cagA* fragment extending from the 67^th^ to the 2313^th^ bp at the 5′ end of the *cagA* gene of *H. pylori* strain 26695. IPTG was added to the LB-Amp broth at 30°C to induce CagA protein expression.

Enzyme-linked immunosorbent assay (ELISA) {#s4_4}
-----------------------------------------

The presences of serum IgG antibodies to the recombinant FliD and CagA were determined by indirect ELISA. Ninety-six-well plates (Costar, USA) were coated with 100 μL/well of purified FliD or CagA protein diluted to 0.5 μg/mL and 0.25 μg/mL, respectively, and incubated overnight at 4°C. After washing three times with 300 μL phosphate-buffered saline tween (PBST) (0.15 mol/L phosphate buffer, 0.05% Tween-20, pH 7.4), the ELISA plates were blocked in a moist chamber with 200 μL PBS containing 1% bovine serum albumin (BSA) (Amresco, USA) per well for 2 hours at 37°C. All serologic samples (3600-fold diluted with 0.1% BSA, phosphate buffer) were then added to the microtiter wells and incubated at 37°C for 1 hour. After three washes, 1:10000 or 1:5000 of 100 μL peroxidase-conjugated goat anti-human IgG (ZSGB-Bio, Beijing, China) were loaded into each well for FliD and CagA, respectively, and the plates were incubated for 30 minutes at 37°C. The plates were washed, and TMB substrate (100 μL) was then added to the plates, which were then incubated at 37°C for 15 minutes. The reaction was terminated with the addition of 50 μL of 2 M sulfuric acid solution. Finally, the density of each serum sample was measured at the dual wavelengths of 450 and 630 nm in a microplate reader (BioTek Synergy 2, USA). Each serum sample was tested in triplicate. Additionally, 100 μL PBS containing 0.1% BSA was added to the wells as a control.

Statistical analysis {#s4_5}
--------------------

We used the t-test to compare the means of the continuous variables between the patients and controls, and the chi-square test was used to compare the distributions of the various characteristics between the different groups. The ELISA values for FliD and CagA were tested with the K-S test following logarithmic conversion. The ELISA result for a patient\'s serum sample was considered positive if the absorbance (OD450) was less than or equal to the optimal cutoff OD value. Unconditional logistic-regression analysis was conducted to assess the associations between FliD, CagA and GC. To determine the relative risks, ORs and 95% confidence intervals (CIs) were calculated. The chi-square trend test was used to measure the dose-response relationships between the serum FliD and CagA antibody levels and GC. The sensitivities, specificities, and AUCs with the 95% CIs were also calculated. Furthermore, the ELISA values for FliD, FlaA, NapA and CagA were combined with discriminant analysis through the predicted probability for each subject. The AUCs of the combinations were also computed. A test result was considered positive if it was less than or equal to a selected predicted probability and negative if it was greater than a selected predicted probability. According to the selected predicted probability, the sensitivities were obtained at set specificities of 90%, 95%, and 98%. All of the above-mentioned statistical analyses were performed with SPSS statistics 17.0, and with *P* values \<0.05 were considered statistically significant.
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FliD

:   flagellar hook-associated protein

CagA

:   cytotoxin-associated gene A

FlaA

:   flagellin A

NapA

:   neutrophil-activating protein

GC

:   gastric cancer

*H. pylori*

:   *Helicobacter pylori*

WHO

:   World Health Organization

IARC

:   International Agency for Research on Cancer

PCR

:   polymerase chain reaction

CAG

:   chronic atrophy gastritis

ELISA

:   enzyme-linked immunosorbent assay

OD

:   optical density

OR

:   odds ratio

CI

:   confidence interval

ROC

:   receiver operating characteristic

AUC

:   area under the ROC curve

SDS-PAGE

:   sodium dodecyl sulfate polyacrylamide gel electrophoresis

PBST

:   phosphate-buffered saline tween

BSA

:   bovine serum albumin

CEA

:   carcinoembryonic antigen

CA19-9

:   cancer antigen 19-9

CA72-4

:   cancer antigen 72-4
